论文部分内容阅读
作者在两组(每组各29例)使用高剂量泼尼松(PDN)或地夫可特(defiazacort,DFZ)的肾病综合征患者中,对不同骨骼的部位核查类固醇的长期功效.在类固醇治疗开始时,患者的骨骼都是正常的.开始时,给予PDN80mg/d,并在1年内逐渐减少到20mg/d;DFZ也给予相等的剂量.PDN组中23例完成了6个月的治疗,DFZ组中18例完成了12个月的治疗.依靠实验室参数,以确保肾病综合征的治疗效果.在治疗的6和12个月中,对骨骼中的矿物质含量(BMC)做了全面检测.两前臂用单光子吸收测定法计算BMC的含量,并通过双光子吸收法测定下颚、前臂及腰椎.由于DFZ潜在的节钙作用,DFZ的功效可与PDN相比拟.在肾病综合征的功效方面两药间并无差异.在使用DFZ治疗的患者中,24h尿蛋白含量从9,9g 降到1.1g,PDN组则从8.og降至1.4g.两组血浆蛋白浓度均正常.经类固醇治疗的两组病人的所有骨骼部位的BMC水平明显下降.不过,在不同的骨骼部位,其骨的衰退率/月有着明显
The authors examined the long-term efficacy of steroids at various bone sites in patients with nephrotic syndrome using high-dose prednisone (PDN) or defiazacort (DFZ) in two groups (n = 29 in each group) At the start of the treatment, the patient’s bones were all normal, initially 80 mg / d of PDN was given and gradually reduced to 20 mg / d within 1 year, and DFZ was given the same dose. Twenty-three of the PDN patients completed 6 months of treatment , And 18 of the DFZ group completed 12 months of treatment, relying on laboratory parameters to ensure the therapeutic effect of nephrotic syndrome. The bone mineral content (BMC) was made at 6 and 12 months of treatment Comprehensive detection of the two forearm with single-photon absorption assay BMC content, and determined by two-photon absorption of the jaw, forearm and lumbar spine due to the potential of DFZ effect of calcium, DFZ efficacy comparable with PDN in nephrotic syndrome Efficacy in terms of no difference between the two drugs in patients treated with DFZ, 24h urinary protein content dropped from 9,9 g 1.1g, PDN group dropped from 8.og to 1.4g plasma protein concentrations were normal in both groups .Bone levels in all skeletal sites of steroid treated patients significantly decreased BMC levels.However, The skeletal sites, the rate of decline in bone / month there is a clear